Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results.

Sara A. Hurvitz,Seock-Ah Im,Yen-Shen Lu,Marco Colleoni,F Franke,Aditya Bardia,Nadia Harbeck,Louis W.C. Chow,Joohyuk Sohn,Keun Seok Lee,Saul Campos Gomez,Rafael Villanueva,Kyung Hae Jung,Arunava Chakravartty,Gareth Hughes,Ioannis Gounaris,Karen Rodriguez-Lorenc,Tetiana Taran,Debu Tripathy

Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results.

2019

Sara A. Hurvitz
Seock-Ah Im
Yen-Shen Lu
Marco Colleoni
F Franke
Aditya Bardia
Nadia Harbeck
Louis W.C. Chow
Joohyuk Sohn
Keun Seok Lee
Saul Campos Gomez
Rafael Villanueva
Kyung Hae Jung
Arunava Chakravartty
Gareth Hughes
Ioannis Gounaris
Karen Rodriguez-Lorenc
Tetiana Taran
Debu Tripathy

LBA1008Background: The phase III MONALEESA-7 study (NCT02278120) is the first dedicated trial of endocrine therapy (ET) ± a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor in premenopausal patients ...

Keywords:

Endocrine system
Pathology
Breast cancer
Ribociclib
Oncology
Medicine
Internal medicine
Kinase
endocrine therapy
overall survival
Cancer
advanced breast

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations